USPTO Patent Application: Systems for Targeting Cancer Cells

ChangeBridge: Patent Apps - Therapeutics (A61P)

Published March 19th, 2026

Detected March 23rd, 2026

Summary

The USPTO has published a new patent application, US20260078200A1, detailing systems and methods for targeting cancer cells using genetically modified immune cells. The application describes novel polypeptides and their use in killing target cancer cells.

View original document View source feed page

What changed

This document is a publication of a United States Patent Application (US20260078200A1) filed on September 17, 2025, and published on March 19, 2026. It describes systems and methods for targeting cancer cells, specifically involving immune cells genetically modified to produce antigen-triggered polypeptides that recognize different cell surface antigens on cancer cells. The application also covers polyspecific-immune inducing polypeptides with antigen binding domains for target cancer cells.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on regulated entities. However, it signifies potential future innovations in cancer therapeutics. Companies involved in drug development, biotechnology, and cancer treatment should be aware of this filing as it may impact their intellectual property landscape and future product development strategies.

Source document (simplified)

← USPTO Patent Applications

SYSTEMS AND METHODS FOR TARGETING CANCER CELLS

Application US20260078200A1 Kind: A1 Mar 19, 2026

Inventors

Wendell A. Lim, Olga G. Troyanskaya, Benjamin Vandersluis, Ruth Dannenfelser

Abstract

The present disclosure provides immune cells genetically modified to produce two antigen-triggered polypeptides, each recognizing a different cell surface antigen, wherein the two different cell surface antigens employed are selected from those pairs described herein. The present disclosure further provides systems comprising two antigen-triggered polypeptides (or nucleic acids encoding same), each recognizing a different cell surface antigen, wherein the two different cell surface antigens employed are selected from those pairs described herein. Also provided are method of killing a target cancer cell, using the described genetically modified immune cells and/or systems. The present disclosure also provides polyspecific-immune inducing polypeptides including first and second antigen binding domains specific for first and second antigens, respectively, present on the surface of a target cancer cell.

CPC Classifications

C07K 16/3015 A61K 39/00 A61K 39/0011 A61K 40/11 A61K 40/31 A61K 40/4202 A61P 35/00 C07K 14/7051 C07K 16/28 C07K 16/40 A61K 2239/31 A61K 2239/38 A61K 2239/47 A61K 2239/49 A61K 2239/54 C07K 2317/31 C07K 2317/622 C07K 2319/00